ARCA biopharma Enters Material Definitive Agreement
Ticker: ORKA · Form: 8-K · Filed: Mar 22, 2024 · CIK: 907654
| Field | Detail |
|---|---|
| Company | Arca Biopharma, Inc. (ORKA) |
| Form Type | 8-K |
| Filed Date | Mar 22, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $8,206.42 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, definitive-agreement
TL;DR
ARCA biopharma just signed a big deal, details TBD.
AI Summary
On March 19, 2024, ARCA biopharma, Inc. entered into a material definitive agreement. The filing does not disclose specific details of the agreement, such as the counterparty or financial terms, but it is categorized under Item 1.01.
Why It Matters
This filing indicates a significant new contract or partnership for ARCA biopharma, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — The lack of specific details in the filing regarding the material definitive agreement introduces uncertainty about its nature and potential impact.
Key Players & Entities
- ARCA biopharma, Inc. (company) — Registrant
- March 19, 2024 (date) — Date of earliest event reported
- March 22, 2024 (date) — Date of Report
FAQ
What is the nature of the material definitive agreement entered into by ARCA biopharma, Inc.?
The filing does not specify the nature of the agreement, only that it is a material definitive agreement under Item 1.01.
Who is the counterparty to this material definitive agreement?
The filing does not disclose the name of the other party involved in the agreement.
What are the key financial terms or obligations associated with this agreement?
The filing does not provide any details regarding the financial terms or obligations of the agreement.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on March 19, 2024.
What is the principal executive office address for ARCA biopharma, Inc.?
The principal executive offices are located at 10170 Church Ranch Way, Suite 100, Westminster, Colorado, 80021.
Filing Stats: 582 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2024-03-22 16:20:11
Key Financial Figures
- $8,206.42 — imum monthly rent shall be increased to $8,206.42. If the Company elects to stay in the p
Filing Documents
- abio-20240319.htm (8-K) — 41KB
- abio-ex10_1.htm (EX-10.1) — 24KB
- 0000950170-24-035373.txt ( ) — 180KB
- abio-20240319.xsd (EX-101.SCH) — 24KB
- abio-20240319_htm.xml (XML) — 5KB
01 Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement. On March 19, 2024, ARCA biopharma, Inc., a Delaware corporation ("ARCA"), entered into the First Amendment to Office Lease Agreement (the "Lease Amendment") with Lotus Church Ranch, LLC (the "Landlord"), which amended that certain Office Lease Agreement, dated as of August 7, 2020, related to the Company's headquarters in Westminster, Colorado (the "Lease"). Under the Lease Amendment, the term of the Lease was extended an additional six (6) months through September 30, 2024 (the "Lease Extension"). Commencing on April 1, 2024, the minimum monthly rent shall be increased to $8,206.42. If the Company elects to stay in the property after the Lease Extension, it will pay rent month to month equal to 125% of the base rent paid in September 2024. The foregoing description of the Lease Amendment does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Lease Amendment, a copy of which is attached as Exhibit 10.1 to this report and is incorporated by reference herein.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 10.1 First Amendment to Office Lease Agreement, dated March 19, 2024, by and between ARCA biopharma, Inc. and Lotus Church Ranch, LLC . 104 Cover Page Interactive Data File. The cover page XBRL tags are embedded within the inline XBRL document (contained in Exhibit 101).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ARCA biopharma, Inc. (Registrant) Date: March 22, 2024 By: /s/ C. Jeffrey Dekker Name: C. Jeffrey Dekker Title: Chief Financial Officer